Camargo

FEBRUARY 10, 2021

Drug development is an extremely cumbersome process, requiring the testing of an agent from in vitro studies to in vivo studies to in silico modeling. Given that it can take up to 20 years for a final product to be approved, it is unsurprising that drug attrition rates are very high. Approaches to Pharmacokinetic Analysis.

Production 133

Production Bioavailability In-Vivo Bioequivalency 133

Camargo

DECEMBER 22, 2021

In addition to prioritizing programs most closely aligned with sponsor objectives, a portfolio analysis can help prevent a program from failing due to misalignment of the various factors that affect drug development, including clinical, nonclinical, regulatory, scientific, manufacturing, and market dynamics. Clinical Pharmacology.

Bioequivalency 169

Bioequivalency Production Genotoxicity In-Vivo 169

Drug Discovery World

AUGUST 3, 2022

CDMO in peptides and oligonucleotides manufacturing, Bachem, has started building a new future for oligonucleotides: solving the industry’s main challenges around capacity, sustainability and cost-effectiveness. Ensuring that the CPP can escape this endosomal compartment is crucial for its bioavailability and bioactivity properties.

Bioavailability 52

Bioavailability In-Vivo RNA In-Vitro 52

Pharmaceutical Technology

MAY 31, 2023

CFT8919 is an orally bioavailable BiDAC degrader designed to exhibit potent and selective activity against EGFR L858R in patients with non-small cell lung cancer (NSCLC). Betta will be responsible for the development, manufacture and commercialisation of CFT8919 in the licensed territories.

Bioavailability 130

Bioavailability In-Vivo In-Vitro Licensing 130

Pharmaceutical Technology

FEBRUARY 13, 2023

Best practice is to also consider the ‘developability’ of the lead compounds in conjunction with any evidence of potential in-vivo activity, by taking a holistic approach. With all this in mind, how do drug developers know which strategy and approach is right for their molecule at this early stage?

Development 130

Development In-Vivo Clinical Trials Clinical Trials 130

Camargo

SEPTEMBER 30, 2021

The drug development process can be broken down into three main disciplines: chemistry, manufacturing, and control (CMC); nonclinical; and clinical. CMC programs include drug substance manufacturing process scale-up, stability testing, early formulation development, and, later on, manufacturing process validation, among other considerations.

Development 201

Development Research Manufacturing In-Vivo 201

Pharmaceutical Technology

FEBRUARY 23, 2023

How does bioavailability play a role in biopharmaceutics? Now fraction absorbed and bioavailability are often confused and used interchangeably. Quotient Sciences helps biotech and pharma customers in the development and optimization of drug products.

Development 246

Development Drugs Bioavailability In-Vivo 246